NEW YORK — For most people, Alexander disease is a name they have never encountered. For the families navigating it, the condition follows a familiar, unrelenting arc: the slowing of movement, the weakening of limbs, the gradual narrowing of what their child can still do. For decades, there was nothing to offer them beyond supportive care.
That changed on September 3, when the U.S. Food and Drug Administration approved ZANVASTRO as the first disease-modifying treatment for Alexander disease, clearing it for use in pediatric and adult patients ages 2 and older. The drug, known generically as zilganersen and developed by Ionis Pharmaceuticals, is the first therapy to target the genetic mechanism driving the disease, a landmark in the treatment of one of the rarest neurological conditions known to medicine.
Alexander disease is caused by mutations in the GFAP gene, which encodes glial fibrillary acidic protein, a structural component of brain cells called astrocytes. When the gene mutates, it produces a misfolded version of the protein that accumulates in the nervous system, driving progressive damage to motor, cognitive, autonomic, and gastrointestinal function. In its most severe infantile form, the disease begins in the first two years of life. In milder cases, onset occurs in adolescence or adulthood. Like the study of Alzheimer’s genetic risk, research on Alexander disease is centered on how specific gene mutations reshape brain protein behavior with far-reaching neurological consequences.
The disease affects roughly one in one million people, placing it firmly among the rarest of rare diagnoses. Only a few hundred patients are estimated to be living with the condition in the United States, a small population that has historically made clinical development difficult to execute and commercially unattractive to fund.
Ionis enrolled 54 patients from 13 sites across 8 countries in the pivotal trial that underpinned the FDA’s decision. Participants ranged in age from 1.5 to 53 years, reflecting the disease’s wide window of onset. The trial randomized patients at a 2-to-1 ratio, with the larger group receiving zilganersen every 12 weeks via an intrathecal injection, delivered directly into the spinal canal, and the remainder assigned to a control group. Patients were followed for 60 weeks before transitioning to an open-label extension. Full details of the study design and outcomes are available in the clinical trial registry.
Among the youngest patients, those between 2 and 4 years of age, the data suggested the drug may do more than stabilize function. The Gross Motor Function Measure-88, which tracks motor development in young children, showed a 22.9-point difference favoring the treated group. Researchers described the finding as potentially meaningful for children diagnosed before significant motor loss has occurred, while cautioning that the trial’s size requires careful interpretation.
Brett P. Monia, chief executive of Ionis Pharmaceuticals, said the approval marks the opening of a new chapter for patients who have spent years without options. “Today’s approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no treatment options,” he said in its press release. He added that the approval also represents Ionis’s first independent commercial launch from its neurology pipeline.
Zilganersen is an antisense oligonucleotide, a class of drug designed to intercept RNA before it is translated into protein. By targeting the GFAP messenger RNA directly, the drug reduces the amount of misfolded protein accumulating in astrocytes, addressing the disease’s molecular origin rather than its downstream effects. The drug is administered as a 50 mg quarterly intrathecal injection, meaning patients receive four doses per year. The advance in targeted neurological approaches is part of a wider shift in the treatment landscape, one that has also seen progress in areas such as oral MS treatment for other conditions that once had few pharmacological options.
Ionis has also secured a licensing agreement with Recordati, an Italian pharmaceutical company focused on rare and specialty diseases, granting Recordati exclusive rights to develop and commercialize zilganersen outside the United States. The agreement, finalized in June 2026, reflects an expectation that the FDA approval will support regulatory submissions in Europe and elsewhere.
What the approval leaves open is the question of access. The cost of the treatment has not been disclosed. How aggressively commercial insurers will cover a drug for a condition this rare remains unknown. Whether the effects observed across a range of patient ages and disease severities in a 54-person trial will hold up in broader clinical practice is a question that only real-world experience can resolve. Emerging research on how neurodegeneration unfolds differently across patient populations, including recent work on dementia risk in aging, suggests that treatments for progressive neurological conditions often perform differently in practice than in controlled trial settings.
For the families who have watched Alexander disease advance without any means of slowing it, the approval of ZANVASTRO is a material change in what medicine can offer. Whether it becomes broadly accessible, whether it performs as well in adults as in children, and how it interacts with the full clinical range of the disease are questions that will take years of evidence to answer.
